Skip to main content

Dr. Malgorzata Mcmasters

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
31
In the NPI registry since
2007
Medicare patients seen, 2024
161

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MA license 240551

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
161
Services billed
693
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes369225
Established patient office or other outpatient visit, 40-54 minutes267112
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes12137
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes1912
New patient office or other outpatient visit, 60-74 minutes1919

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Jakafi (ruxolitinib phosphate)27
Acyclovir
Other prescribers in Boston, MA
17
Eliquis (apixaban)
Other prescribers in Boston, MA
13
Prednisone
Other prescribers in Boston, MA
12
Venclexta (venetoclax)12
Rezurock (belumosudil mesylate)11
Bosulif (bosutinib)11
Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim)
Other prescribers in Boston, MA
11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $327,716 in research payments for these studies, mostly to the institutions running them.

  • A15-873;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
    AbbVie Inc.
  • A15-873;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets
    AbbVie Inc.
  • A15-873;Venclexta;Blister Card: ABT-199 100mg Tablet, 1x8 Tablets
    AbbVie Inc.
  • A Phase Ib Study of the Combination of Venetoclax with Chemotherapy as Frontline Therapy in Older Patients with Acute Lymphoblastic Leukemia (ALL)
    AbbVie Inc.
  • A15-873;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets
    AbbVie Inc.
  • A15-873;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets
    AbbVie Inc.
  • STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
    Stemline Therapeutics Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 4, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1588878029. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.